Due to increasing regulatory requirements, the need for quality study and patient safety data is critical as we work together to bring our clients’ novel treatments to patients. PRA Health Sciences is diligently working to meet our clients’ data demands through the substantial growth of our Data Monitoring Committee (DMC) services over recent years. Staffed by a global team of experts, PRA’s dedicated DMC Unit ensures our clients’ projects meet the most stringent regulatory requirements.
Mindfulness with Roger Pelletier
Stop—take a breath. Notice it. Notice your body relax. Become aware of where you are. Acknowledge your thoughts, but don’t cling to them. Let them go.
Predicting Screen Failure Rates of Human Abuse Potential Studies
Human Abuse Potential (HAP) studies are required for New Drug Approvals of all drugs that have a potential psychoactive effect. The steps of…
Opportunities in low-level radiocarbon microtracing: applications and new technology
14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation,…